Grant: Master's Award: Canada Graduate Scholarships
McMaster University
$17,500.00
The Role of Escherichia virus T4 in Reducing Murine Experimental Melanoma Metastasis
FY 2023-24
Summary
Viruses can be used to target and interact with cancer cells (Budynek et al., 2010). The current clinical use of oncolytic viruses, which infect and destroy cancer cells, demonstrates that they can be used as an effective cancer therapeutic option (Santos Apolonio et al., 2021). However, oncolytic viruses that are engineered versions of human pathogenic viruses can risk a viral infection. Bacteriophages (or phages) are viruses that infect bacteria; they cannot infect animal cells because of major differences in bacterial and animal replicative machinery (Budynek et al., 2010). Phages could be used to develop viruses to target cancers without the risk of infection and resulting side effects. Escherichia virus T4 is a phage that has been shown to help delay colon cancer growth in mice, by aiding immune cells in mounting an anti-tumor response (Pajtasz-Piasecka et al., 2008). T4 also binds to melanoma cells, which are cancerous cells of a dangerous type of skin cancer, through interactions between phage proteins and ?3-integrins on the cells. (Gorski et al., 2003; Heistein et al., 2023). ?3-integrins are adhesion molecules that bind to fibrinogen, a protein complex, to facilitate melanoma metastasis, or tumor migration and establishment in a secondary site in the body (Huang & Rofstad, 2018). Metastasis can dramatically decrease life expectancy for patients (Dawes et al., 2016). The observation that T4 reduces tumor metastasis by blocking ?3-integrins from binding to fibrinogen has not been fully investigated in vivo in mouse models. Further research in this area would provide important insights on whether T4 can be further explored as a therapeutic that addresses a debilitating stage of cancer progression.
Department
Program
Master's Award: Canada Graduate Scholarships
Recipient
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
506294
Name
Umair Ayesha
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
The Role of Escherichia virus T4 in Reducing Murine Experimental Melanoma Metastasis
Programtype2
Studentship Programs
Orgnameinp2
McMaster University
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Bacteriophage; Melanoma; Metastasis; Oncology; Oncolytic Virus; Phage Therapy; Virology
Abstract
Viruses can be used to target and interact with cancer cells (Budynek et al., 2010). The current clinical use of oncolytic viruses, which infect and destroy cancer cells, demonstrates that they can be used as an effective cancer therapeutic option (Santos Apolonio et al., 2021). However, oncolytic viruses that are engineered versions of human pathogenic viruses can risk a viral infection. Bacteriophages (or phages) are viruses that infect bacteria; they cannot infect animal cells because of major differences in bacterial and animal replicative machinery (Budynek et al., 2010). Phages could be used to develop viruses to target cancers without the risk of infection and resulting side effects. Escherichia virus T4 is a phage that has been shown to help delay colon cancer growth in mice, by aiding immune cells in mounting an anti-tumor response (Pajtasz-Piasecka et al., 2008). T4 also binds to melanoma cells, which are cancerous cells of a dangerous type of skin cancer, through interactions between phage proteins and ?3-integrins on the cells. (Gorski et al., 2003; Heistein et al., 2023). ?3-integrins are adhesion molecules that bind to fibrinogen, a protein complex, to facilitate melanoma metastasis, or tumor migration and establishment in a secondary site in the body (Huang & Rofstad, 2018). Metastasis can dramatically decrease life expectancy for patients (Dawes et al., 2016). The observation that T4 reduces tumor metastasis by blocking ?3-integrins from binding to fibrinogen has not been fully investigated in vivo in mouse models. Further research in this area would provide important insights on whether T4 can be further explored as a therapeutic that addresses a debilitating stage of cancer progression.
Competitiondate
202312
Approvedterm2
1 yr 0 mth
Pinamesdelim
Umair, Ayesha
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~